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1. Introduction 
Cardiorenal syndrome (CRS) describes the inter-relationship and complex 
pathophysiological processes by which dysfunction of either the heart or the kidneys is 
related to dysfunction in the other organ system. Historical definitions may have been 
overly simplistic; newer definitions have tried to capture the complex interactions and 
feedback processes which exist between the two organs. These definitions classify the CRS 
into five discrete categories, based on both the organ system in which the primary 
dysfunction occurs and the time course of disease development/progression.  
The CRS is more common than many clinicians realize. Over one third of patients in heart 
failure (HF) registries have evidence of renal dysfunction, and a similar proportion of 
dialysis patients have symptoms of congestive HF or clinical evidence of left ventricular 
dysfunction (Adams et al., 2005; Stack & Bloembergen, 2001). Importantly, the presence of 
the CRS is a strong adverse prognostic marker in patients with either primary cardiac 
disease or primary renal disease. 
While originally thought to reflect renal hypoperfusion secondary to low cardiac output, it 
is now understood that the CRS is underpinned by far more complex processes. From a 
hemodynamic standpoint, it seems likely that venous congestion is at least as important to 
the pathophysiology of disease progression as is low forward flow. Other contributing 
factors include activation of neurohormonal axes, including the sympathetic nervous system 
and the renin-angiotensin-aldosterone system, as well as oxidative injury and endothelial 
dysfunction (Bock & Gottlieb, 2010). More recently, it has become recognized that anemia 
may also be intimately involved in the process, both as a consequence and as a causative 
agent of the CRS. Finally, it is well recognized that many common risk factors for 
cardiovascular disease and for chronic kidney disease (CKD) co-exist in these patient 
cohorts. 
Management of the CRS is challenging. Therapies for HF often cause worsening of renal 
function, while treatment of renal failure commonly involves fluid administration, which 
may precipitate disease decompensation among those with HF. Unfortunately, most large 
randomized trials in the HF population have excluded patients with elevated serum 
creatinine levels, and there is little evidence to guide therapy in this group of patients. 
Observational studies suggest that there may be a mortality benefit associated with the use 
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of standard HF medications, such as angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers and beta blockers in patients with HF and CKD, regardless of glomerular 
filtration rate (GFR) (Berger et al., 2007; Cice et al., 2003).  
Many novel therapies for HF have been introduced over recent years, several of which were 
appealing for treatment of the CRS, given the pathophysiological processes towards which 
they were directed. Unfortunately, natriuretic peptides, vasopressin antagonists, and 
adenosine antagonists have all failed to show meaningful clinical benefits in patients with 
HF (Hernandez, 2010; Konstam et al., 2007; Massie et al., 2010). Other approaches, 
particularly peripheral ultrafiltration, have shown more promise in this patient population 
(Costanzo et al., 2005). 
2. Definitions and sub-types of the cardiorenal syndrome 
Historically, the CRS is thought to have been due to impaired renal perfusion secondary to 
low cardiac output states or the result of HF therapies negatively impacting renal function. 
In 2004, the National Heart, Lung and Blood Institute defined CRS as a “state in which 
therapy to relieve heart failure symptoms is limited by further worsening in renal function” 
(National Heart, Lung and Blood Institute, 2004). By this paradigm, the heart was 
considered to be the central driving force behind impaired renal function in patients with 
HF. 
Our understanding of the pathophysiology behind the CRS has evolved in the last number 
of years and there is increasing recognition of the complexity of interactions which exist 
between the heart and the kidneys, particularly when either or both organs are diseased. 
This organ cross talk is bidirectional in nature and the resultant dialogue is dependent on 
whether the heart or the kidney is the primary affected organ as well as the time course over 
which the associated pathophysiological changes may occur. 
It is within this context, that newer definitions for the CRS have been proposed which 
recognize that either the heart or kidney may be the primary site of organ injury. A more 
comprehensive definition and classification schema for the CRS has the advantage of 
allowing clinicians to make a more accurate diagnosis which in turn informs our 
understanding of a given patient’s natural history, prognosis and optimal treatment 
strategy. 
The definition and classification system for CRS introduced by Ronco and colleagues in 2008 
(Ronco et al., 2008) is now widely considered to be the preferred mechanism for describing 
patients and the pathophysiological processes associated with CRS. Ronco and colleagues 
broadly define CRS as “a pathophysiological disorder of the heart and kidneys whereby 
acute or chronic dysfunction of one organ may induce acute or chronic dysfunction of the 
other.” Additionally, they characterize five sub-types of the CRS based on this definition. 
These are described and discussed below. It should be noted that CRS types 1-5 may 
frequently co-exist in a given patient, underscoring the complexity of interaction between 
the heart and kidney and the importance of appointing chronology to these processes. 
2.1 Cardiorenal syndrome type 1 (acute cardiorenal syndrome) 
Type 1 CRS is distinguished by an acute deterioration in cardiac function or acute cardiac 
injury, from any cause, that secondarily results in acute kidney injury (AKI). 
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Pathophysiologically, Type 1 CRS is characterized by decreased cardiac output with 
impaired renal perfusion as well as elevated central venous pressures and acute renal 
edema. Renal ischemia may be mediated by decreased oxygen delivery due to impaired 
myocardial contractile performance, elevated interstitial pressures in the renal medulla and 
by peripheral/systemic vasoconstriction which occurs as a compensatory mechanism in the 
face of low cardiac output. 
Historically, decreased forward cardiac flow was thought to be the primary determinant for 
AKI in this context, however recent clinical trials have suggested this mechanism may not 
be as important in the development of CRS Type I as previously hypothesized. Specifically, 
data from ADHERE (Acute Decompensated Heart Failure National Registry) which 
included over 100,000 patients admitted to hospital in the United States with acute 
decompensated heart failure (ADHF) showed that <2% of patients had systemic 
hypotension, a surrogate for low cardiac output, while the vast majority of patients had 
symptoms/signs of volume overload (Adams et al., 2005). This is corroborated by the 
findings of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary 
Artery Catheterization Effectiveness) Trial in which 433 patients admitted to hospital with 
ADHF were randomized to pulmonary artery catheterization versus standard care to assess 
the efficacy of tailored haemodynamic therapy (Binanay et al., 2005). In the ESCAPE Trial, 
cardiac index was not associated with baseline renal function or deterioration in renal 
function, however right atrial pressure was weakly correlated with baseline creatinine and 
GFR (Nohria et al., 2008). 
The impact of central venous pressures (CVP) on worsening renal function in the setting of 
ADHF has been receiving greater attention in recent years. Elevated CVP is more predictive 
of a decline in renal function than other relevant haemodynamic variables such as cardiac 
index, blood pressure and pulmonary capillary wedge pressure (Mullens et al., 2009). 
Moreover, elevated CVP predicts risk of re-hospitalization for HF and death suggesting that 
it is a potent prognosticator for poor outcomes and a potential target for therapy (Uthoff et 
al., 2011). Elevated intra-abdominal venous pressures have also been shown to have a 
similar relationship with GFR at baseline and changes in GFR with therapy (Bock & 
Gottlieb, 2010; S. E. Bradley & G. P. Bradley). This may be the result of a direct mechanical 
effect on renal blood flow or simply a reflection of elevated CVP. 
Among patients with ADHF, activation of the sympathetic nervous system (SNS) and the 
renin-angiotensin-aldosterone system (RAAS) is a homeostatic mechanism intended to 
maintain intraglomerular perfusion pressures and preserve GFR. Paradoxically however, 
systemic vasoconstriction by these mechanisms increases cardiac afterload leading to further 
decline in cardiac output and renal blood flow. Additionally, these neurohormones have a 
maladaptive effect on the myocardium resulting in fibrosis and ventricular remodeling. 
Treatment with ǃ-blockers is relatively contra-indicated in the face of an acute 
decompensation due to their negative inotropic effects and the relative dependence of 
cardiac output on heart rate in this patient population; therefore, SNS activation in CRS 
Type 1 may remain unchecked leading to ischemia of both renal and cardiac tissue beds. 
Acute administration of RAAS inhibition may exacerbate renal injury in CRS Type 1 by 
reducing pressure in Bowman’s capsule; this effect may be magnified in the presence of 
volume shifts associated with diuretics, which remains the mainstay of therapy. Moreover, 
diuretics may directly result in additional neurohormonal activation and there is now an 
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increasing body of literature suggesting that diuretics, in and of themselves, may be 
associated with worse outcomes in patients with ADHF independent of other relevant 
clinical variables. In a single centre retrospective analysis of 1354 patients admitted with 
ADHF, Eshaghian and colleagues (Eshaghian et al., 2006) demonstrated that patients 
requiring the highest doses of diuretics, stratified by quartiles, had higher rates of sudden 
death, death due to progressive pump failure and all cause mortality compared to patients 
in the lowest quartile of diuretic dose. This type of observation has fueled a growing interest 
in identifying alternate strategies for fluid management in the acute setting, independent of 
diuretic administration (see section 3.8). 
Of particular concern among patients who present with the features of CRS Type 1 is the 
impact of diagnostic imaging and invasive cardiac procedures which may have an 
additional and direct toxic effect on the kidneys through a variety of mechanisms. 
Individuals who present with an acute deterioration in cardiac function will frequently 
require imaging or investigation to identify a precipitant or cause for their symptoms. 
Independently, percutaneous interventions and cardiac surgery impart a risk of AKI which 
is higher in patients who have pre-existing or concomitant acute renal insufficiency 
(Anderson et al., 1999; Best et al., 2002). 
Upwards of 70% of patients admitted to hospital with ADHF will experience a rise in serum 
creatinine over the course of their admission (Gottleib et al., 2002); this may be the result of 
therapies administered, either medical or invasive, or a consequence of the various 
pathophysiological processes which characterize CRS Type 1. Regardless of mechanism, 
worsening renal function portends a poor prognosis and is associated with higher mortality 
rates. (Gottleib et al., 2002; Damman et al., 2007).  
2.2 Cardiorenal syndrome type 2 (chronic cardiorenal syndrome) 
Chronic HF leading to chronic kidney disease is the hallmark of CRS Type 2. The prevalence 
of CKD in HF cohorts has been variably reported depending on the patient population 
examined – e.g. hospitalized versus ambulatory patients. Further complicating our 
understanding of disease prevalence is the fact that early clinical trials of chronic HF 
excluded patients with established renal insufficiency and most did not determine 
glomerular filtration rate (GFR) which is of particular clinical importance given that HF is a 
disease of the elderly.  
For example, the SOLVD (Studies of Left Ventricular Dysfunction) trials examined the impact 
of the angiotensin converting enzyme (ACE) inhibitor Enalapril on mortality and symptom 
development in patients with left ventricular dysfunction (The SOLVD Investigators, 1991; The 
SOLVD Investigators, 1992). While those with serum creatinine levels >2.0 mg/dL were 
excluded from the original trial, a retrospective analysis of study patients revealed at least 
moderate renal impairment (GFR < 60 ml/min) was present in 26% and 56% of participants in 
the prevention and treatment arms of the trial, respectively (Dries et al., 2000). Across the 
series of trials which composed the CHARM (The Candesartan in Heart Failure: Assessment of 
Reduction in Mortality and Morbidity) Program, moderate renal impairment was detected in 
36% of the 2680 study participants at baseline (Hillege et al., 2006). 
Determining the prevalence of pre-existing CKD is particularly challenging among 
hospitalized HF patients. Some clinicians may attribute AKI at the time of HF 
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hospitalization solely to CRS Type 1 thereby underestimating the presence of concomitant 
CRS Type 2 in this cohort of patients. Novel biomarkers of AKI may help clinicians to 
decipher the relative contributions of CRS Type 1 versus CRS Type 2 in patients hospitalized 
for HF who have poor renal function upon presentation (Siew et al., 2011; Coca et al., 2008).  
Regardless of cause, renal insufficiency in hospitalized HF patients appears to be relatively 
common; among those enrolled in ADHERE, the prevalence of at least moderate renal 
impairment, as determined by GFR, was greater than 60% at baseline (Heywood et al., 2007). 
This is in sharp contrast to initial reports from the same registry which suggested a 
prevalence rate of only 20% when a serum creatinine of 2.0 mg/dL was employed as a cut 
off (Adams et al., 2005). Calculation of GFR, therefore, is paramount to accurately 
identifying the burden of renal disease in all forms of CRS. 
The true burden of pre-existing renal dysfunction among patients with HF was best 
characterized in a meta-analysis performed by Smith and colleagues. In their systematic 
review of the literature, approximately 80,000 hospitalized and non-hospitalized patients 
with HF were identified across 16 clinical trials. While 29% of patients were found to have 
moderate to severe renal impairment (GFR <53 mL/min or cystatin C of >1.56 mg/dL), 63% 
were found to have at least some degree of impaired kidney function. Moreover, these 
findings are likely to underestimate the true prevalence of renal insufficiency in HF 
populations given that 8 of the clinical trials included in the meta-analysis excluded patients 
on the basis of age or an elevated serum creatinine at baseline (Smith et al., 2006). 
In the meta-analysis performed by Smith and colleagues, renal impairment at baseline 
conferred an increased risk of mortality at one year follow-up compared to patients with 
normal kidney function (Smith et al., 2006). The adjusted hazard ratio for patients with any 
renal impairment or moderate to severe renal impairment was 1.56 and 2.31 respectively. 
Excess risk was conferred in an incremental fashion with each 10 mL/min reduction in GFR 
correlating to a 7% increase in the risk of death. This observation is strengthened by similar 
findings across a spectrum of clinical trials in both hospitalized and ambulatory HF 
populations (Adams et al., 2005; Dries et al., 2000; Fonarow et al., 2005; Heywood et al., 2007; 
Hillege et al., 2006). 
Many of the pathophysiological mechanisms which characterize CRS Type 1 are also 
implicated in the development of CRS Type 2, although many of these processes may occur 
slowly and over longer periods of time. For example, elevated central venous pressure is 
strongly associated with a decline in eGFR among patients with chronic HF (Damman et al., 
2009; Firth et al., 1988); as described above, the same is true for patients with ADHF and 
CRS Type 1. Elevated CVP and secondarily an elevation in renal venous pressure may 
trigger a number of downstream events, including interstitial ischemia, neurohormonal 
activation and decreased responsiveness to natriuretic peptides which all combine to reduce 
GFR directly or indirectly (Damman et al., 2007; Bock & Gottlieb, 2010) in the setting of 
chronic HF. Chronically low cardiac output, particularly in combination with micro and 
macrovascular renal disease, may also contribute to fibrosis and structural changes in the 
kidney which result in impaired renal function. 
RAAS activation occurs in both HF and CKD with an associated increase in Angiotensin II 
levels (AII). AII mediates oxidative injury and endothelial dysfunction through both the 
formation of reactive oxygen species and a decrease in nitric oxide bioavailability. Each of 
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these processes, in turn, can result in haemodynamic abnormalities at the level of the heart 
and kidney contributing to a decline in GFR (Bock & Gottlieb, 2010). 
While neurohormonal inhibition and diuretic therapy are the mainstay of pharmacological 
HF management, these agents are also implicated in the worsening of GFR associated with 
CRS Type 2. ACE inhibitors and angiotensin receptor blockers (ARBs) result in systemic 
hypotension as well as efferent arteriolar vasodilatation with an associated decline in 
intraglomerular pressure and GFR. These effects may be magnified in the presence of 
concomitant diuretic use and relative intra-vascular volume depletion. The treatment of CRS 
is discussed in detail below. 
The presence of anemia is common in patients with HF, an observation which is consistent 
across a number of clinical trials in the HF arena. A review of the literature suggests a 
prevalence rate of between 9-25% depending on the HF patient population studied and the 
cut-off criteria used to diagnose anemia (Virani et al., 2008; Al-Ahmad et al., 2001; Sharma et 
al., 2004; Anand et al., 2005; Horwich et al., 2002). Regrettably, many of these studies 
excluded patients based on renal function and therefore the relative contribution of low GFR 
to the development of anemia in these patient cohorts is lacking. Anemia in the presence of 
HF portends a poor prognosis with absolute haemoglobin (Hgb) levels correlating with 1 
year survival; a precipitous increase in mortality is observed when Hgb drops below 120 
g/L (Horwich et al., 2002; Ezekowitz et al., 2003).  
The development of anemia in CRS Type 2 is likely multifactorial and underpinned by a 
number of processes occurring simultaneously; malnutrition, the formation of reactive 
oxygen species, cytokine release and erythropoietin (EPO) deficiency/resistance have all 
been implicated. When present, anemia may lead to further cardiac and renal dysfunction 
through impaired oxygen delivery and tissue hypoxia, neurohormonal activation, decreased 
renal blood flow and expansion of plasma volume with resultant cardiac remodeling 
(McCullough & Lepor, 2005). These mechanisms establish and propagate a vicious cycle of 
maladaptive processes which lead to worsening anemia, HF and kidney function as a net 
result. 
2.3 Cardiorenal syndrome type 3 (acute renocardiac syndrome) 
The RIFLE Criteria define acute kidney injury as a twofold increase in serum creatinine or a 
GFR decrease by 50 percent or urine output of <0.5 mL/kg per hour for 12 hours (Bellomo et 
al., 2004). By this definition, AKI is prevalent in nearly 9% of hospitalized patients (Uchino 
et al., 2006) with an associated 4-fold increased risk of mortality compared to patients 
without evidence of renal injury (Ricci et al., 2008). Much of that excess risk may be 
attributable to cardiac sequelae of AKI. CRS Type 3 characterizes this interaction and may be 
defined broadly as primary acute kidney injury, due to any number of causes, which 
secondarily leads to acute cardiac dysfunction. 
A number of pathophysiological processes may be initiated as a consequence of AKI which 
have significant downstream cardiac effects. Biochemical abnormalities including 
hyperkalemia may pre-dispose to malignant cardiac arrhythmias and an increased risk of 
sudden cardiac death. Acidemia and uremia have direct myocardial depressant effects and 
may precipitate acute biventricular cardiomyopathy; these effects are exacerbated in the face 
of volume expansion.  
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Volume overload due to impaired solute and fluid clearance may also result in hypertension 
and pulmonary edema. Moreover, the resultant elevations in intra-cardiac filling pressures 
reduce the transmyocardial perfusion gradient during diastole leading to sub-endocardial 
ischemia and overall worsening of ventricular function. Release of pro-inflammatory 
cytokines and reactive oxygen species in response to renal injury may result in endothelial 
dysfunction in addition to having direct toxic effects on the myocardium with resultant 
apoptosis and myocardial fibrosis. 
Activation of the SNS and RAAS as a result of AKI may also lead to deleterious 
haemodynamic consequences including increased systemic vascular resistance and 
increased myocardial oxygen consumption, both of which lead to decreased cardiac output. 
While AII also causes left ventricular hypertrophy, ventricular remodeling and accelerates 
the development of atherosclerosis, these effects are likely of greater relevance in the setting 
of Chronic Renocardiac Syndrome (CRS Type 4). 
2.4 Cardiorenal syndrome type 4 (chronic renocardiac syndrome) 
CRS Type 4 describes a clinical scenario where primary CKD leads to structural and/or 
functional cardiac abnormalities which may be associated with clinically significant adverse 
cardiac events. Indeed, the presence of CKD portends a poor cardiac prognosis with the 
attributable risk of adverse events correlating in a step-wise manner to reduction in GFR (Go 
et al., 2004). Moreover, individuals with CKD have an accelerated natural history of their 
cardiac disease and are more likely to die from cardiac causes rather than progress to renal 
replacement therapy (Collins et al., 2008; Foley et al., 2005; Keith et al., 2004). 
For example, in ALLHAT (The Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial) the risk of myocardial infarction (MI)/stroke, revascularization, death 
due to coronary disease and all forms of atherosclerotic vascular disease was increased as 
GFR decreased (Wali & Henrich, 2005). Among patients with CKD who experience an acute 
coronary syndrome, prognosis may also be stratified according to GFR. Shlipak and 
colleagues reviewed approximately 130,000 elderly patients hospitalized with an acute 
coronary syndrome and found a 2.5 fold increased risk of death between patients in the 
highest (CrCl > 0.92 mL/sec) and lowest (CrCl 0.17-0.54 mL/sec) tertile of creatinine 
clearance (Shlipak et al., 2002). Moreover, an analysis of nearly 120,000 patients from the 
Cooperative Cardiovascular Project suggested that renal function was a more accurate 
predictor of long term mortality post-MI than left ventricular systolic function, the presence 
of heart failure or prior MI (Smith et al., 2008). This relationship has been demonstrated in a 
multitude of clinical trials across a variety of cardiac cohorts and the observation between 
CKD and poor cardiac outcomes remains robust (Ronco et al., 2008). 
There are many postulates as to the mechanisms underlying poor cardiac outcomes in 
patients with chronic renal dysfunction. It would appear that the burden of coronary artery 
disease and myocardial ischemia is greater in patients with CKD than those without (Ix et 
al., 2003). This may be due to a higher preponderance of traditional risk factors for coronary 
artery disease in this patient population (Muntner et al., 2005; Parikh et al., 2006) or simply 
that CKD, in and of itself, imparts increased risk of adverse cardiac events (Levey et al., 
2003). In the Framingham Offspring Cohort, two or more traditional cardiovascular risk 
factors were identified in 73% of patients with CKD (GFR <60 mL/min) compared to 51.4 % 
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of participants without CKD. A statistically significant increase in hypertension and diabetes 
along with a trend towards increased dyslipidemia were more prevalent in the CKD cohort 
(Parikh et al., 2006). Existing data would suggest that CKD is independently associated with 
a higher risk for cardiovascular endpoints in affected patients; the magnitude of this excess 
risk, however, does not support elevating CKD to the level of a cardiovascular disease 
equivalent as is the case with diabetes or prior MI (Wattanakit et al., 2006). 
Other potential pathophysiological processes involved in the development and acceleration 
of coronary atherosclerosis in patients with CKD include abnormalities of mineral 
metabolism leading to vascular calcification and endothelial dysfunction secondary to both 
chronic inflammation and EPO deficiency. Uremia, hypertension and increased vascular 
stiffness contribute to progressive left ventricular hypertrophy and diastolic dysfunction, 
which in time may progress to systolic dysfunction. Neurohormonal activation results in 
myocardial fibrosis and maladaptive ventricular remodelling which may hasten this 
process. In the presence of volume expansion, patients with either systolic or diastolic 
dysfunction remain at high risk for developing decompensated heart failure.  
Observational trials very clearly demonstrate that those with CKD, as a result of actual or 
perceived contraindications, are less likely to receive efficacious and evidence based 
therapies compared to cohorts of patients with normal renal function (Al-Suwaidi et al., 
2002; Parikh et al., 2006). An even more important observation is that those patients with 
CKD who do receive appropriate guideline based interventions have better outcomes 
(Shlipak et al., 2002); therapeutic prejudice of healthcare teams and providers in relation to 
patients with renal dysfunction is most certainly misplaced, particularly since this group of 
patients have a high burden of disease and therefore may receive the greatest degree of 
benefit from aggressive intervention. 
2.5 Cardiorenal syndrome type 5 (secondary cardiorenal syndrome) 
Secondary cardiorenal syndrome is the result of a systemic disorder leading to simultaneous 
cardiac and renal injury; each of these processes may be acute or chronic in nature and CRS 
Type 5 does not preclude involvement of other organs and tissue beds. Moreover, other sub-
types of the CRS may exist concomitantly due to pre-existing co-morbidities. 
The prevalence of CRS Type 5 overall has not been well described, primarily due to a 
paucity of data in this arena, however the frequency of cardiac and renal involvement for 
specific systemic disease states may be described in the literature. For example, myocardial 
injury in the absence of an acute coronary syndrome, as manifested by a positive troponin 
assay, is present in up to one-half of patients with sepsis admitted to a critical care unit 
(Amman et al., 2003). Similarly, AKI may occur in 70% of this patient population (Kim et al., 
2011). Dysfunction of either or both organ systems portends a poor prognosis. 
Connective tissue disease, sarcoidosis, amyloidosis, diabetes and sepsis are the most 
commonly referred to systemic process that may predispose to secondary CRS (Ronco et al., 
2008). While a discussion of cardiac and renal involvement in each of these disease states is 
beyond the scope of this chapter, it is clear that definitive treatment must be focused at 
correcting the underlying pathophysiological process while providing supportive care for 
the heart and kidneys in the interim. 
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3. Management of the cardiorenal syndrome 
Management of the CRS presents a challenge to the clinician. Treatment of HF with 
standard therapies often results in worsening of renal function. Moreover, most randomized 
clinical trials of HF therapies, including ǃ-blockers, ACE inhibitors, ARBs and aldosterone 
antagonists, have excluded patients with significant renal dysfunction. Therefore, the results 
of these trials, most showing significant reductions in morbidity and mortality in the general 
HF population, may not be applicable to the CRS population. Observational studies and 
small randomized studies, however, have suggested that many of these drug classes may 
have similar benefit in patients with renal dysfunction (Berger et al., 2007; Cice et al., 2003). 
A number of novel strategies have been described that may offer specific benefit in the CRS 
population, although data from clinical trials have not always been encouraging. 
Management of chronic CRS is overall similar to the management of HF in general, 
employing a combination of diuretics, inhibitors of the RAAS, and ǃ-blockers. In the 
hospitalized patient with CRS and ADHF, diuretics remain a mainstay of therapy, but may 
be supplemented by additional therapies including novel pharmacologic agents, inotropic 
support, and ultrafiltration.  
3.1 Diuretics 
While fluid removal with diuretics is a cornerstone of HF management, diuretic resistance is 
highly prevalent in patients with decreased renal function, making this aspect of care for the 
patient with CRS particularly challenging. Furthermore, effective diuresis can result in 
further deterioration in renal function, particularly when the rate of fluid removal exceeds 
the rate of fluid movement from the extravascular space to the intravascular space, resulting 
in low effective circulating volume. Thus, two of the greatest obstacles in treating patients 
with CRS are overcoming diuretic resistance and effectively removing fluid without 
compromising renal function. 
Loop diuretics (LD) such as furosemide act at the thick ascending limb of the loop of Henle, 
inhibiting the Na+/K+/2Cl- cotransporter. LD are protein bound, preventing filtration at the 
glomerulus, but are actively secreted in the proximal tubule. Effective delivery to the loop of 
Henle requires effective delivery to the bloodstream (through intestinal absorption or direct 
intravenous administration), adequate renal blood flow, intact proximal tubule secretion, 
and delivery of tubular contents to the more distal nephron. There are therefore a number of 
mechanisms by which diuretic resistance may occur (Jentzer et al., 2010). 
Delayed intestinal absorption is common in patients with HF, owing to intestinal wall 
edema. This can be most effectively overcome by using intravenous LD in patients who are 
markedly volume overloaded, and transitioning to oral administration once signs of 
congestion elsewhere (i.e. peripheral edema, venous congestion on chest X-ray) have 
resolved. Reduced renal blood flow (RBF) and GFR are also prevalent in patients with HF 
and CRS as a result of intrinsic renal dysfunction, decreased cardiac output, and alteration 
in glomerular haemodynamics by agents such as non-steroidal anti-inflammatory drugs 
(NSAIDs), ACE inhibitors, and ARBs. Avoiding agents such as NSAIDs, optimizing 
systemic hemodynamics, and increasing LD dose can help to overcome this aspect of 
resistance to LD. Similarly, proximal tubular secretion of LD is reduced in patients with CRS 
www.intechopen.com
 Chronic Kidney Disease 
 
132 
because organic acids that accumulate in the uremic state compete for the same transporters; 
increased doses of LD may be required to overcome this problem. 
Through intravascular volume depletion, LD may result in activation of the RAAS. This 
leads to increased sodium absorption by the proximal and distal tubule. This issue is 
compounded by the fact that post-diuretic rebound sodium avidity occurs between bolus 
doses of LD, negating much of the natriuretic benefit achieved. Strict dietary sodium 
restriction and administration of RAAS antagonists (i.e. ACE inhibitors and ARBs) may help 
to prevent this. Historically, it has been believed that continuous infusions of diuretics may 
also be effective in minimizing rebound sodium absorption; the recent DOSE (Diuretic 
Strategies in Patients with Acute Decompensated Heart Failure) trial suggests that there 
may be no difference in diuretic efficacy between intermittent intravenous bolus dosing and 
continuous infusions (Felker et al., 2011). 
The “braking phenomenon” is a short-term effect, whereby the nephron becomes less 
sensitive to LD after an initial dose. This is thought to result from upregulation of the 
Na+/K+/2Cl- cotransporter in the thick ascending loop of Henle. Higher doses of LD may be 
necessary to overcome this. With chronic LD administration, distal tubule hypertrophy 
occurs. This allows increased distal sodium reabsorption, tending to negate the inhibition of 
sodium reabsorption that has occurred in the loop of Henle.  
A strategy of combination diuretic administration, with the addition of a thiazide diuretic 
such as metolazone 5-10 mg 30 minutes prior to LD administration can help to prevent 
sodium retention by this mechanism. Thiazides inhibit the NaCl cotransporter in the distal 
convoluted tubule. Caution is needed, however, as combination diuretic therapy can result 
in profound electrolyte abnormalities. Serum levels of potassium and magnesium must be 
closely monitored and infrequent metolazone dosing (i.e. three times per week) or co-
administration of a potassium-sparing diuretic may be necessary to prevent life-threatening 
hypokalemia.  
Finally, sodium and water retention may be upregulated in the distal nephron in patients 
with CRS, mediated by elevated levels of aldosterone and vasopressin, respectively. 
Administration of aldosterone antagonists or other potassium-sparing diuretics will 
minimize sodium retention in this situation; the new vasopressin antagonists have a role in 
preventing excessive absorption of free water (see section 3.6). Free water restriction may 
also be necessary in patients with refractory fluid overload or significant hyponatremia. An 
important caveat to the use of aldosterone antagonists in CRS is the risk of hyperkalemia in 
patients with renal impairment; these agents should generally be avoided in patients with 
GFR <30 mL/min. 
Major drawbacks to the use of LD include neurohormonal activation, ototoxicity, electrolyte 
abnormalities (particularly hypokalemia and hypomagnesemia), dysrhythmias, and 
intravascular volume depletion with resultant worsening renal function and/or 
hypotension in patients who are preload-dependent or receiving concomitant vasodilator 
therapy.  
A novel approach to diuretic use involves the co-administration of loop diuretics and 
hypertonic saline solution (HSS). Small studies in patients with ADHF have demonstrated 
that, compared to intravenous bolus loop diuretics with a low sodium diet, administration 
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of intermittent boluses of HSS with loop diuretics and moderate dietary sodium restriction 
resulted in more rapid diuresis, normalization of neurohormonal activity, shorter 
hospitalizations, and less renal dysfunction (Licata et al., 2003; Paterna et al., 2000). After 
discharge, these results were maintained by continuing moderate sodium restriction (<2.8 
g/day) with strict fluid restriction (<1 L/day), resulting in fewer readmissions and 
improved survival compared to continued strict sodium (<2 g/day) and similar fluid 
restriction. The mechanism by which HSS provides these benefits is unclear, but may be 
related to the osmotic load drawing interstitial fluid into the intravascular space, leading to 
neurohormonal blockade, reduced vascular resistance, improved cardiac output, and 
reduced interstitial edema. In addition, the sodium load in the kidney may induce a sort of 
transient diabetes insipidus, resulting in rapid diuresis (Di Pasquale et al., 2007). Further 
research and larger scale studies are required to confirm the benefits of HSS in patients with 
CRS. 
3.2 Renin-angiotensin-aldosterone system antagonists 
Inhibitors of the renin-angiotensin system, including ACE inhibitors and ARBs have proven 
survival benefit in patients with left ventricular dysfunction (The SOLVD Investigators, 
1991; The SOLVD Investigators, 1992), and have also been shown to slow the rate of decline 
of renal function in patients with diabetic chronic kidney disease (Lewis et al., 1993). It 
stands to reason, therefore, that these agents would be beneficial in the CRS, although large-
scale clinical trials in the HF population have typically excluded patients with significant 
renal dysfunction.  
The CHARM studies investigated the effects of candesartan compared with placebo in a 
broad population of patients with HF. Patients with serum creatinine >3.0 mg/dL were 
excluded, but among the study population, there was no statistically significant interaction 
between eGFR and treatment effect, suggesting a mortality benefit of ARBs in patients with 
HF and mild-to-moderate renal dysfunction that is equivalent to that seen in patients with 
HF and preserved renal function (Hillege et al., 2006). An analysis of CONSENSUS 
(Cooperative North Scandinavian Enalapril Survival Study) which demonstrated a mortality 
benefit of enalapril compared to placebo in patients with HF, found a greater benefit in 
patients with baseline serum creatinine above the median (123 umol/L) than in those with 
serum creatinine below the median (Swedberg et al., 1990). A retrospective analysis of the 
Minnesota Heart Survey stratified 4573 patients hospitalized with HF by GFR, and revealed 
that patients at all stages of CKD had reduced in-hospital mortality when an ACE inhibitor 
or ARB was used in hospital, and reduced one-year mortality when discharged on an ACE 
inhibitor or ARB (Berger et al., 2007). This same analysis, however, demonstrated that 
patients with severe renal dysfunction were far less likely to receive either agent than those 
with normal renal function. 
In HF, elevated angiotensin II levels cause efferent arteriolar vasoconstriction, elevating 
glomerular filtration pressure and preserving GFR. Inhibition of this process with ACE 
inhibitors or ARBs may result in an initial decline in GFR, but in the long term protects the 
glomerulus from high filtration pressures and may help to preserve long-term renal 
function (Heywood, 2004). Although there appear to be benefits of using these agents in the 
CRS population, caution must be taken when initiating ACE inhibitors and ARBs in patients 
with renal dysfunction, particularly with regard to volume status and avoidance of NSAIDs. 
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Volume depletion increases the risk of significant renal dysfunction associated with ACE 
inhibitors and ARBs. Increases in creatinine of up to 30% are acceptable, and may identify a 
group of patients most likely to benefit from angiotensin inhibition (Koniari et al., 2010). HF 
patients who are unable to tolerate ACE inhibitor therapy because of hypotension, renal 
dysfunction, or hyperkalemia have a particularly high one-year mortality rate, in excess of 
50% (Kittleson et al., 2003). 
3.3 -adrenergic receptor blockers 
ǃ-blockers are considered standard therapy in patients with HF and systolic dysfunction. 
They exert a number of beneficial effects, including prevention of ventricular arrhythmias, 
prevention of ventricular remodeling, reduction in myocardial oxygen demand, increased 
myocardial oxygen supply, and inhibition of other deleterious neurohormonal pathways. 
Their significant mortality benefit in patients with HF is well established through large 
clinical trials. Unfortunately, the majority of these studies excluded patients with significant 
renal dysfunction, but retrospective analyses of trials data have offered insight into the 
benefits in patients with mild-to-moderate renal impairment. COPERNICUS (Carvedilol 
Prospective Randomized Cumulative Survival Study), for example, demonstrated a 35% 
reduction in the risk of death in patients with severe HF treated with carvedilol compared to 
placebo, but excluded patients with a serum creatinine greater than 2.8 mg/dL. Similarly, 
the CAPRICORN (Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction) 
trial showed a 23% reduction in all-cause mortality in patients with EF ≤40% after 
myocardial infarction treated with carvedilol compared with placebo, but excluded patients 
with significant renal impairment (Dargie, 2001). A post-hoc analysis of individual patient 
data from these two trials, however, demonstrated that in patients with HF and mild-to-
moderate CKD, carvedilol was safe and efficacious, associated with reductions in all-cause 
mortality, cardiovascular mortality, and HF hospitalization (Wali et al., 2011). CIBIS-II (The 
Cardiac Insufficiency Bisoprolol Study II) demonstrated a 34% reduction in mortality in 
patients with HF treated with bisoprolol compared to placebo, and excluded patients with 
serum creatinine ≥300 umol/L (3.4 mg/dL) (CIBIS-II Investigators and Committees, 1999). A 
post-hoc analysis of this trial showed that although patients with GFR <60 mL/min had 
higher overall mortality than those with GFR ≥60 mL/min, the benefit of bisoprolol was 
similar in both groups (Erdmann et al., 2001). The relative risk of mortality in the group with 
GFR <60 mL/min treated with bisoprolol compared to placebo was 0.66, and there was a 
non-significant trend towards an even greater benefit in the small number of patients with 
GFR <30 mL/min.  
An analysis of MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II), which 
demonstrated a 31% reduction in the risk of all-cause mortality with the addition of an 
implantable cardioverter-defibrillator to medical therapy in patients with ischemic 
cardiomyopathy and EF ≤30%, examined the predictors of sudden cardiac death (SCD) in 
the subset of patients in the medical arm of the study with impaired renal function, defined 
as GFR ≤75 mL/min. ǃ-blocker therapy was a negative predictor of SCD, with a hazard ratio 
of 0.61 (Chonchol et al., 2007).  
Smaller studies have examined the benefits of ǃ-blocker therapy in patients with end-stage 
renal failure. In a non-randomized study of 134 patients with HF and either chronic renal 
impairment, anemia, or both, treatment with ǃ-blockers for 12 months was associated with 
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improvement in both creatinine clearance and hemoglobin levels, while those patients who 
did not receive ǃ-blockers had worsening renal function and anemia over the same time 
period (Khan et al., 2006). In patients with HF and normal renal function at baseline, lack of 
treatment with a ǃ-blocker was associated with increased risk of developing renal failure 
over 20 years of follow-up (Tanaka et al., 2007). In hemodialysis patients with dilated left 
ventricles, treatment with metoprolol resulted in reduced ventricular dimensions, increased 
fractional shortening, and reduced levels of natriuretic peptides (Hara et al., 2001). A 
randomized trial of 114 hemodialysis patients with dilated cardiomyopathy showed that 
carvedilol, compared to placebo, was associated with improved ejection fraction, improved 
survival, and fewer HF hospitalizations (Cice et al., 2003). Although large-scale clinical trials 
in this population are lacking, the weight of evidence suggests that treatment with ǃ-
blockers in the CRS population is likely to be associated with reductions in mortality and 
morbidity. 
3.4 Inotropic agents 
Inotropic medications such as dobutamine and milrinone are frequently used in patients 
with ADHF, particularly in the setting of the CRS where low cardiac output is felt to be a 
major contributor to rapidly declining renal function. Both agents are vasodilating 
inotropes, but they have different mechanisms of action. Dobutamine is an adrenergic 
agonist that affects inotropy and chronotropy via ǃ-1 activity and peripheral vasodilation 
via ǃ-2 activity. Milrinone is an inhibitor of type III phosphodiesterase and results in 
increased intracellular cyclic adenosine monophosphate (cAMP). This, in turn, results in 
increased inotropy (without chronotropy) as well as peripheral vasodilation. Although both 
agents have attractive hemodynamic profiles in the treatment of CRS, evidence suggests that 
they should not be part of standard therapy in this condition. OPTIME-CHF (Outcomes of a 
Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) 
compared intravenous milrinone to placebo in patients with ADHF not requiring inotropic 
therapy for shock or other indications. There was no difference between the two groups in 
the primary endpoint of total number of days in hospital by 60 days after randomization. 
There was also no difference in the rate of progression of HF, but the patients treated with 
milrinone had higher rates of treatment failure, largely driven by higher rates of 
hypotension and atrial arrhythmias.  
The ADHERE registry compared outcomes of patients with ADHF treated with vasodilating 
medications (nitroglycerin, nesiritide) and inotropic agents (dobutamine, milrinone). Even 
after adjustment for baseline variables including age, gender, blood pressure, BUN, 
creatinine, sodium, heart rate, and symptom severity, odds ratios for mortality between 
individual inotropes and individual vasodilators ranged from 1.45 to 2.17. Inotropic agents, 
therefore, are recommended by major society guidelines only for short-term use in patients 
with cardiogenic shock or refractory volume overload with diuretic resistance, and not 
recommended for routine use in hospitalized patients with ADHF. In addition, patients 
receiving these agents must be carefully monitored for hypotension and arrhythmias, and it 
should be recognized that the use of these agents is associated with a worse prognosis. 
Dopamine is an endogenous catecholamine that binds dopamine receptors (D1-D5) as well 
as ǂ and ǃ adrenergic receptors with varying affinity depending on the dose administered. 
At low doses (2-5 mcg/kg/min), it primarily binds dopaminergic receptors and causes 
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vasodilation of renal, splanchnic, cerebral, and coronary vessels. At higher doses, ǃ 
adrenergic effects dominate, resulting in positive inotropy and chronotropy as well as ǃ 
adrenergic-mediated vasodilation, with progressively increasing ǂ adrenergic activity at still 
higher doses resulting in vasoconstriction.  
For many years the use of “renal-dose” dopamine was advocated in acute renal failure, the 
rationale being that dopamine in doses up to 5 mcg/kg/min in animals and healthy 
volunteers resulted in increased renal blood flow and natriuresis via selective dopamine 
receptor binding. In recent years this approach has fallen out of favor, as multiple 
retrospective and small prospective studies failed to convincingly demonstrate any benefit 
in terms of renal function or survival. A meta-analysis of 61 trials comparing low-dose 
dopamine to placebo or no treatment found that dopamine was associated with a 24% 
increase in urine output on day 1 but was not associated with reductions in mortality, need 
for renal replacement therapy, or adverse events (Friedrich et al., 2005). Only one of the 61 
studies included patients with HF, and this study did not assess mortality; only three of the 
studies included patients who were receiving diuretics. More recently, data from the DAD-
HF (Dopamine in Acute Decompensated Heart Failure) trial has been presented, comparing 
low-dose dopamine plus low-dose furosemide to high-dose furosemide alone in patients 
with ADHF. The two regimens were not associated with statistically significant rates of 
diuresis, but the patients receiving dopamine plus low-dose furosemide were less likely to 
develop worsening renal function (36% and 4% of patients in dopamine/furosemide and 
furosemide only groups, respectively, had >25% increase in serum creatinine). As more data 
become available regarding outcomes with low-dose dopamine in this specific population, 
“renal-dose” dopamine may turn out to be useful after all.  
3.5 Vasodilators 
Nesiritide, a synthetic B-type natriuretic peptide (BNP), has been used in the management of 
ADHF, particularly in patients at risk for worsening renal function with standard therapies. 
Like naturally occurring BNP, released from ventricular myocardium under conditions of 
increased wall stress, nesiritide is a vasodilator, causing both arterial and venous dilatation 
as well as mild diuresis. Its rapid onset of action, apparent neurohormonal benefits, and lack 
of need for invasive hemodynamic monitoring led to much initial enthusiasm for its use in 
ADHF, as well as FDA approval for this indication (Publication Committee for the VMAC 
Investigators, 2002). Use of this agent took a sharp decline, however, after meta-analyses 
suggested increased 30-day mortality and increased risk of renal failure with nesiritide 
(Hauptman et al., 2006; Sackner-Bernstein et al., 2005a; 2005b). The definitive randomized 
clinical trial, ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure), recently demonstrated that while nesiritide is safe with no 
increased risk of 30-day death or hospitalization or increased risk of renal failure, it offers no 
significant clinical benefit when added to standard therapy in patients with ADHF 
(Hernandez, 2010). 
3.6 Vasopressin antagonists 
Arginine vasopressin (AVP), a nonapeptide synthesized by the hypothalamus and released 
by the posterior pituitary gland in response to increased plasma osmolality or decreased 
plasma volume, binds to 3 distinct receptor subtypes (V1a, V1b, and V2). V1 receptors 
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mediate cardiac myocyte hypertrophy, vasoconstriction, and platelet aggregation. When 
AVP binds V2 receptors expressed in the renal collecting duct, the short-term result is 
increased translocation of vesicles containing aquaporin-2 (AQP2) water channels to the 
apical membrane of principal cells; in the long-term, AVP-V2 receptor binding results in the 
up-regulation of AQP2 protein expression. AQP2 mediates water transport across the apical 
membrane of the principal cell, resulting in urinary concentration and increased solute-free 
water retention (Schrier et al., 2009). AVP also stimulates urea reabsorption, resulting in an 
augmented medullary concentrating gradient and increased levels of blood urea nitrogen 
(Sands, 2003). 
In HF and CRS, low cardiac output causes nonosmotic AVP release, leading to 
inappropriate water retention. Low serum sodium and elevated blood urea nitrogen are 
strong predictors of mortality in HF, and both are mediated, at least in part, by AVP activity 
in the kidney. Augmentation of cardiac output with vasodilator medications is associated 
with reductions in plasma AVP (Bichet et al., 1986). Early studies demonstrated effective 
water removal without worsening renal function (Gheorghiade et al., 2007). Thus, the use of 
agents that interfere with AVP-mediated water retention has been an attractive concept in 
CRS. The SALT-1 and SALT-2 trials showed that tolvaptan, a selective oral V2 receptor 
antagonist, caused increases in serum sodium levels in patients with HF, cirrhosis, and the 
syndrome of inappropriate antidiuretic hormone (Schrier et al., 2006). Unfortunately, the 
randomized EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome 
Study with Tolvaptan) trial subsequently failed to demonstrate a mortality benefit or 
reduction in HF morbidity in patients hospitalized with HF treated with tolvaptan, despite 
sustained reductions in body weight with preserved renal function (Konstam et al., 2007). It 
seems, therefore, that vasopressin antagonists have little role in influencing clinical 
outcomes in patients hospitalized with HF and the CRS, although they may be useful in 
patients with hyponatremia that is difficult to manage with standard therapies. Additional 
studies are needed to further define the role of tolvaptan and other vasopressin antagonists 
in the outpatient setting. 
3.7 Adenosine antagonists 
Adenosine is a purine nucleoside breakdown product of adenosine triphosphate. It interacts 
with four main receptor subtypes: A1, A2a, A2b, and A3. With the exception of coronary 
vasodilatation and increased renal medullary blood flow, its cardiovascular and renal effects 
are largely mediated via the A1 receptor. Binding of adenosine to A1 receptors in the heart 
results in slowing of the heart rate and decreased atrial contraction. In the kidney, adenosine 
is released from the macula densa in response to sodium delivery to the distal nephron via 
tubuloglomerular feedback (TGF). Adenosine released through TGF acts on local A1 
receptors, causing afferent arteriolar vasoconstriction and reduction in GFR as well as 
increased proximal tubular sodium reabsorption. Blockade of these receptors should, 
therefore, result in improved renal blood flow and GFR and decreased sodium and water 
reabsorption.  
In the setting of CRS, loop diuretics cause increased sodium delivery to the distal tubule, 
making the role of adenosine particularly relevant in this population. Animal studies 
showed that rolofylline, a selective A1 receptor antagonist, caused increased urine flow and 
urinary sodium excretion without increasing potassium excretion and without affecting 
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either blood pressure or renal function, and protected against nephrotoxic medication-
induced acute renal failure (Nagashima & Karasawa, 1996; Yao et al., 1994). A small clinical 
study supported this, demonstrating that the addition of rolofylline to diuretics in patients 
with volume overload and renal impairment resulted in an improvement in renal function 
and increased diuresis with reduced diuretic requirements (Givertz et al., 2007). 
Unfortunately, the PROTECT (Placebo-Controlled Randomized Study of the Selective A₁ 
Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute 
Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on 
Congestion and Renal Function) study, which randomized 2033 patients with ADHF to 
intravenous rolofylline or placebo, failed to demonstrated any difference between groups in 
the primary endpoint of treatment success (moderate or marked improvement in dyspnea at 
24 and 48 hours without treatment failure), treatment failure (death or readmission for HF 
by 7 days, persistent worsening renal failure, or worsening HF), or no change (Massie et al., 
2010). There were no differences in the number of patients who developed renal impairment 
or in the secondary endpoint of death or rehospitalization for cardiac or renal causes at 60 
days. The overall adverse event rates were similar between groups, although more patients 
in the rolofylline group had seizures, a known side effect of A1 antagonists mediated via 
central nervous system A1 receptors that regulate electrical excitability. Based on the lack of 
clinical efficacy, coupled with the increased risk of seizures, rolofylline is not recommended 
for the treatment of CRS. 
Another intravenous selective A1 antagonist, tonapofylline, was also investigated in Phase II 
clinical trials after preclinical studies and small human studies suggested effective 
natriuresis. The TRIDENT-1 (Safety and Tolerability of IV Tonapofylline in Subjects With 
Acute Decompensated Heart Failure and Renal Insufficiency) and POSEIDON (Oral BG9928 
in Patients with Heart Failure and Renal Insufficiency) trials were both terminated early 
after review of interim safety data from TRIDENT-1 revealed that two patients in the 
tonapofylline group had had seizures (Ensor & Russell, 2010). Of note, seizures were not 
reported in studies of oral tonapofylline, and in rat studies, tonapofylline did not cross the 
blood-brain barrier (Ensor & Russell, 2010). There is insufficient data to determine whether 
oral formulations of A1 antagonists are safe or clinically useful. 
3.8 Ultrafiltration 
Extracorporeal fluid removal has been used for decades in ADHF, typically reserved for 
patients with fluid overload states that are refractory to diuretics and other medical 
therapies. Small studies of ultrafiltration in HF have previously demonstrated effective fluid 
removal, rapid symptom improvement, attenuated neurohormonal activity, and 
hemodynamic improvements including reduced LV filling pressures and reduced 
pulmonary arterial pressures without reductions in systemic blood pressure or cardiac 
index (Marenzi et al., 1993; Rimondini et al., 1987). The landmark UNLOAD (Ultrafiltration 
versus intravenous diuretics for patients hospitalized for acute decompensated heart failure) 
trial randomized 200 patients with ADHF and volume overload to veno-venous 
ultrafiltration or intravenous diuretics (Costanzo et al., 2005). Patients in both groups had 
similar improvements in dyspnea scores, but the patients in the ultrafiltration group had 
greater weight loss and net fluid loss at 48 hours. Importantly, there were fewer 
rehospitalizations, rehospitalization days, and unscheduled clinic visits at 90 days in the 
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ultrafiltration group than in the IV diuretic group. No differences in renal outcomes were 
seen. 
Ultrafiltration can be performed via peripheral or central veins, with rates of fluid removal 
regulated by a hematocrit sensor and ranging from 10 to 500 mL per hour. Blood flow rates 
range from 10 to 40 mL per minute, and total extracorporeal blood volume can be as low as 
33 mL. Maintenance of a constant hematocrit ensures that the rate of fluid removal from the 
intravascular compartment is equivalent to the rate of fluid shift from the extravascular to 
intravascular compartments. Low extracorporeal blood volume and slow fluid removal 
minimize neurohormonal activation and prevent hypotension. In contrast to the hypotonic 
fluid removal that occurs with diuresis, ultrafiltration removes isotonic fluid, potentially 
resulting in greater total sodium removal. The mechanism of the sustained benefit seen in 
the UNLOAD trial is thought to be related to the attenuation of neurohormonal activity and 
to the removal of isotonic fluid. 
The major limitation to the widespread use of ultrafiltration in HF and the CRS is likely to 
be the cost of the filters used. In addition, questions remain about patient selection, optimal 
timing of initiation of therapy, and determination of total fluid volume to be removed. The 
specific role of ultrafiltration in patients who develop worsening renal function with diuretic 
therapy is being investigated in CARESS-HF (Cardiorenal Rescue Study in Acute 
Decompensated Heart Failure), and will help to define the role of this therapy specifically in 
the CRS population. 
3.9 Erythropoietin and correction of anemia 
Anemia is common in both HF and CKD, and the term “cardiorenal-anemia syndrome” 
refers to the coexistence of anemia and the CRS. EPO is widely used in the CKD population 
to correct anemia to a moderate degree. Studies in this population have shown improved 
parameters of cardiac performance with EPO therapy, including reduction of left ventricular 
hypertrophy and dilatation, improved left ventricular ejection fraction, and increased 
cardiac output (Linde et al., 1996; Low et al., 1989; Low-Friedrich et al., 1991). Studies of 
EPO and iron administration to patients with HF with or without CKD have shown 
inconsistent results, but some studies have demonstrated modest improvements in 
symptoms and functional capacity as well as renal function, ejection fraction, and left 
ventricular dimensions (Bolger et al., 2006; Palazzuoli et al., 2006; Silverberg et al., 2000; 
Toblli et al., 2007). The FAIR-HF (Ferric Carboxymaltose in Patients with Heart Failure and 
Iron Deficiency) study demonstrated improved symptoms and functional capacity in 
patients with HF and iron deficiency, even in the absence of overt anemia, treated with 
intravenous iron as compared to placebo (Anker et al., 2009). The ongoing IRON-HF (Iron 
Supplementation in Heart Failure Patients With Anemia) and RED-HF (Reduction of Events 
With Darbepoetin Alfa in Heart Failure ) studies will likely further clarify the role of iron 
and EPO therapies in patients with HF and provide additional insights into the 
management of the CRS. 
4. Conclusions and future directions 
The Cardiorenal Syndrome is a pathophysiologic state involving complex feedback 
processes between the failing heart and failing kidneys, and is associated with a 
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significantly increased risk of morbidity and mortality compared to either disease process 
alone. New classification schemes add to our understanding of the processes involved, and 
help to guide therapy. As the pathophysiology of the CRS becomes better understood, there 
is potential for the development of novel and rational treatment strategies. Although many 
promising agents introduced in recent years have produced disappointing results in clinical 
trials, other strategies, including HSS, ultrafiltration, and low-dose dopamine still hold 
potential. Larger scale trials of these and other agents are required before their use can be 
widely adopted. Fortunately, such trials are already underway for ultrafiltration, EPO, and 
dopamine and the results of these studies are eagerly anticipated. Similarly, established 
therapies such as ǃ-blockers, ACE inhibitors, and ARBs must be rigorously tested in patients 
with concomitant cardiac and renal dysfunction to ensure they provide clinical benefit 
across the spectrum of disease states which characterize the cardiorenal syndrome. 
5. References 
Adams, K. F., Fonarow, G. C., Emerman, C. L., LeJemtel, T. H., Costanzo, M. R., Abraham, 
W. T., Berkowitz, R. L., Galvao, M., Horton, D. P. ; ADHERE Scientific Advisory 
Committee and Investigators. (2005). Characteristics and outcomes of patients 
hospitalized for heart failure in the United States: rationale, design, and 
preliminary observations from the first 100,000 cases in the Acute Decompensated 
Heart Failure National Registry (ADHERE). Am Heart J, 149(2), 209–16.  
Al-Ahmad, A., Rand, W. M., Manjunath, G., Konstam, M. A., Salem, D. N., Levey, A. S. & 
Sarnak, M. J. (2001). Reduced kidney function and anemia as risk factors for 
mortality in patients with left ventricular dysfunction. J Am Coll Cardiol, 38(4), 955-
62. 
Al-Suwaidi, J., Reddan, D. N., Williams, K., Pieper, K. S., Harrington, R. A., Califf, R. M., 
Granger, C. B., Ohman, E. M., Holmes, D. R.; GUSTO-IIb, GUSTO-III, PURSUIT. 
Global Use of Strategies to Open Occluded Coronary Arteries. Platelet 
Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin 
Therapy; PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the 
Reduction of Acute coronary syndrome events in a Global Organization Network. 
(2002) Prognostic implications of abnormalities in renal function in patients with 
acute coronary syndromes. Circ, 106(8), 974-80. 
Ammann, P., Maggiorini, M., Bertel, O., Haenseler, E., Joller-Jemelka, H. I., Oechslin, E., 
Minder, E. I., Rickli, H. & Fehr, T. (2003). Troponin as a risk factor for mortality in 
critically ill patients without acute coronary syndromes. J Am Coll Cardiol, 41(11), 
2004-9. 
Anand, I. S., Kuskowski, M. A., Rector, T. S., Florea, V. G., Glazer, R. D., Hester, A., Chiang, 
Y. T., Aknay, N., Maggioni, A. P., Opasich, C., Latini, R. & Cohn, J. N. (2005). 
Anemia and change in hemoglobin over time related to mortality and morbidity in 
patients with chronic heart failure: results from Val-HeFT. Circ, 112(8), 1121-7.  
Anderson, R. J., O'brien, M., MaWhinney, S., VillaNueva, C. B., Moritz, T. E., Sethi, G. K., 
Henderson, W. G., Hammermeister, K. E., Grover, F. L. & Shroyer, A. L. (1999). 
Renal failure predisposes patients to adverse outcome after coronary artery bypass 
surgery. VA Cooperative Study #5. Kidney Int, 55(3), 1057-62. 
www.intechopen.com
 Sub-Types and Therapeutic Management of the Cardiorenal Syndrome 
 
141 
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., 
Luscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B. A., Mori, C., von 
Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P. (2009). 
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J 
Med, 361(25), 2436-48. 
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P.; Acute Dialysis Quality 
Initiative Workgroup (2004). Acute renal failure - definition, outcome measures, 
animal models, fluid therapy and information technology needs: the Second 
International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) 
Group. Crit Care, 8(4), R204-12. 
Berger, A. K., Duval, S., Manske, C., Vazquez, G., Barber, C., Miller, L., & Luepker, R. V. 
(2007). Angiotensin-converting enzyme inhibitors and angiotensin receptor 
blockers in patients with congestive heart failure and chronic kidney disease. 
American Heart Journal, 153(6), 1064-73. 
Best, P. J., Lennon, R., Ting, H. H., Bell, M. R., Rihal, C. S., Holmes, D. R. & Berger, P. B. 
(2002). The impact of renal insufficiency on clinical outcomes in patients 
undergoing percutaneous coronary interventions. J Am Coll Cardiol, 39(7), 1113-9. 
Bichet, D. G., Kortas, C., Mettauer, B., Manzini, C., Marc-Aurele, J., Rouleau, J. L. & Schrier, 
R. W. (1986). Modulation of plasma and platelet vasopressin by cardiac function in 
patients with heart failure. Kidney Int, 29(6), 1188-96. 
Binanay, C., Califf, R. M., Hasselblad, V., O'Connor, C. M., Shah, M. R., Sopko, G., 
Stevenson, L. W., Francis, G. S., Leier, C. V. & Miller, L. W.; ESCAPE Investigators 
and ESCAPE Study Coordinators. (2005). Evaluation study of congestive heart 
failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. 
JAMA, 294(13), 1625-33. 
Bolger, A. P., Bartlett, F. R., Penston, H. S., O'Leary, J., Pollock, N., Kaprielian, R., & 
Chapman, C. M. (2006). Intravenous iron alone for the treatment of anemia in 
patients with chronic heart failure. J Am Coll Cardiol, 48(6), 1225-7. 
Bock, J. S. and Gottlieb, S. S. (2010). Cardiorenal syndrome: new perspectives. Circ, 121(23), 
2592-600. 
Bradley, S.E. and Bradley, G.P. (1947). The effect of increased intra-abdominal pressure on 
renal function. Am J Physiol, 26(5), 1010-22. 
Chonchol, M., Goldenberg, I., Moss, A. J., McNitt, S., & Cheung, A. K. (2007). Risk factors for 
sudden cardiac death in patients with chronic renal insufficiency and left 
ventricular dysfunction. Am J Nephrol, 27(1), 7-14. 
Cice, G., Ferrara, L., D'Andrea, A., D'Isa, S., Di Benedetto, A., Cittadini, A., Russo, P. E., 
Golino, P., & Calabro, R. (2003). Carvedilol increases two-year survivalin dialysis 
patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am 
Coll Cardiol, 41(9), 1438-44. 
Collins, A. J., Li, S., Gilbertson, D. T., Liu, J., Chen, S. C. & Herzog, C. A. (2008). Chronic 
kidney disease and cardiovascular disease in the Medicare population. Kidney Int 
Suppl, 87, S24-31. 
www.intechopen.com
 Chronic Kidney Disease 
 
142 
Coca, S. G., Yalavarthy, R., Concato, J. & Parikh, C. R. (2008). Biomarkers for the diagnosis 
and risk stratification of acute kidney injury: a systematic review. Kidney Int, 73(9), 
1008-16. 
Committees, C.-I. I. a. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a 
randomised trial. Lancet, 353(9146), 9-13. 
Costanzo, M. R., Saltzberg, M., O'Sullivan, J., & Sobotka, P. (2005). Early ultrafiltration in 
patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol, 
46(11), 2047-51. 
Damman, K., Navis, G., Smilde, T. D., Voors, A. A., van der Bij, W., van Veldhuisen, D. J. & 
Hillege H. L. (2007). Decreased cardiac output, venous congestion and the 
association with renal impairment in patients with cardiac dysfunction. Eur J Heart 
Fail, 9(9), 872-8. 
Damman, K., Navis, G., Voors, A. A., Asselbergs, F. W., Smilde, T. D., Cleland, J. G., van 
Veldhuisen, D. J. & Hillege, H. L. (2007). Worsening renal function and prognosis 
in heart failure: systematic review and meta-analysis. J Card Fail, 13(8), 599-608. 
Damman, K., van Deursen, V. M., Navis, G., Voors, A. A., van Veldhuisen, D. J. & Hillege, 
H. L. (2009). Increased central venous pressure is associated with impaired renal 
function and mortality in a broad spectrum of patients with cardiovascular disease. 
J Am Coll Cardiol, 53(7), 582-8. 
Dargie, H. J. (2001). Effect of carvedilol on outcome after myocardial infarction in patients 
with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet, 
357(9266), 1385-90. 
Di Pasquale, P., Sarullo, F. M., & Paterna, S. (2007). Novel strategies: challenge loop diuretics 
and sodium management in heart failure--part II. Congest Heart Fail, 13(3), 170-6. 
Dries, D. L., Exner, D. V., Domanski, M. J., Greenberg, B. & Stevenson, L. W. (2000). The 
prognostic implications of renal insufficiency in asymptomatic and symptomatic 
patients with left ventricular systolic dysfunction. J Am Coll Cardiol, 35(3), 681-9. 
Ensor, C. R., & Russell, S. D. (2010). Tonapofylline: a selective adenosine-1 receptor 
antagonist for the treatment of heart failure. Expert Opin Pharmacother, 11(14), 2405-
15. 
Erdmann, E., Lechat, P., Verkenne, P., & Wiemann, H. (2001). Results from post-hoc 
analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with 
chronic heart failure. Eur J Heart Fail, 3(4), 469-79. 
Eshaghian S., Howrich, T. B. & Fonarow, G. C. (2006). Relation of loop diuretic dose to 
mortality in advanced heart failure. Am J Cardiol, 97(12), 1759-64.  
Ezekowitz, J. A., McAlister, F. A. & Armstrong, P. W. (2003) Anemia is common in heart 
failure and is associated with poor outcomes: insights from a cohort of 12, 065 
patients with new-onset heart failure. Circ, 107(2), 223-5. 
Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., 
LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, 
A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., 
Semigran, M. J., Bart, B. A., Mascette, A. M., Braunwald, E., & O'Connor, C. M. 
(2011). Diuretic strategies in patients with acute decompensated heart failure. N 
Engl J Med, 364(9), 797-805. 
www.intechopen.com
 Sub-Types and Therapeutic Management of the Cardiorenal Syndrome 
 
143 
Firth, J. D., Raine, A. E. & Ledingham, J. G. (1988). Raised venous pressure: a direct cause of 
renal sodium retention in oedema? Lancet, 1(8593), 1033-5. 
Foley, R. N., Murray, A. M., Li, S., Herzog, C. A., McBean, A. M., Eggers, P. W. & Collins, A. 
J. (2005). Chronic kidney disease and the risk for cardiovascular disease, renal 
replacement, and death in the United States Medicare population, 1998 to 1999. J 
Am Soc Nephrol, (16)2, 489-95. 
Fonarow, G. C., Adams, K. F., Abraham, W. T., Yancy, C. W. & Boscardin, W.J.; ADHERE 
Scientific Advisory Committee, Study Group, and Investigators. (2005) Risk 
Stratification for in-hospital mortality in acutely decompensated heart failure: 
classification and regression tree analysis. JAMA, 293(5), 572-80. 
Friedrich, J. O., Adhikari, N., Herridge, M. S., & Beyene, J. (2005). Meta-analysis: low-dose 
dopamine increases urine output but does not prevent renal dysfunction or death. 
Ann Intern Med, 142(7), 510-24. 
Gheorghiade, M., Konstam, M. A., Burnett, J. C., Jr., Grinfeld, L., Maggioni, A. P., Swedberg, 
K., Udelson, J. E., Zannad, F., Cook, T., Ouyang, J., Zimmer, C., & Orlandi, C. 
(2007). Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in 
patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA, 
297(12), 1332-43. 
Givertz, M. M., Massie, B. M., Fields, T. K., Pearson, L. L., & Dittrich, H. C. (2007). The 
effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal 
function in patients with acute decompensated heart failure and renal impairment 
or diuretic resistance. J Am Coll Cardiol, 50(16), 1551-60. 
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. (2004). Chronic kidney 
disease and the risks of death, cardiovascular events, and hospitalization. NEJM, 
351(13), 1296-305. 
Gottlieb, S. S., Abraham, W., Butler, J., Forman, D. E., Loh, E., Massie, B. M., O'connor, C. M., 
Rich, M. W. , Stevenson, L. W. , Young, J. & Krumholz, H. M. (2002). The prognostic 
importance of different definitions of worsening renal function in congestive heart 
failure. J Card Fail, 8(3), 136-41. 
Hara, Y., Hamada, M., Shigematsu, Y., Murakami, B., & Hiwada, K. (2001). Beneficial effect 
of beta-adrenergic blockade on left ventricular function in haemodialysis patients. 
Clin Sci (Lond), 101(3), 219-25. 
Hauptman, P. J., Schnitzler, M. A., Swindle, J., & Burroughs, T. E. (2006). Use of nesiritide 
before and after publications suggesting drug-related risks in patients with acute 
decompensated heart failure. JAMA, 296(15), 1877-84. 
Hernandez, A. F. (2010). Acute Study of Clinical Effectiveness of Nesiritide in Decompensated 
Heart Failure Trial (ASCEND-HF)—Nesiritide or placebo for improved symptoms and 
outcomes in acute decompensated HF. Paper presented at the American Heart 
Association 2010 Scientific Sessions.  
Heywood, J. T. (2004). The cardiorenal syndrome: lessons from the ADHERE database and 
treatment options. Heart Failure Reviews, 9(3), 195-201. 
Heywood, J. T., Fonarow, G. C., Costanzo, M. R., Mathur, V. S., Wigneswaran, J. R., Wynne, 
J.; ADHERE Scientific Advisory Committee and Investigators. (2007). High 
prevalence of renal dysfunction and its impact on outcome in 118, 465 patients 
www.intechopen.com
 Chronic Kidney Disease 
 
144 
hospitalized with acute decompensated heart failure: a report from the ADHERE 
database. J Card Fail, 13(6), 422-30. 
Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J., Yusuf, S., Granger, C. 
B., Michelson, E. L., Ostergren, J., Cornel, J. H., de Zeeuw, D., Pocock, S., & van 
Veldhuisen, D. J. (2006). Renal function as a predictor of outcome in a broad 
spectrum of patients with heart failure. Circulation, 113(5), 671-8. 
Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R. & Borenstein J. (2002). 
Anemia is associated with worse symptoms, greater impairment in functional 
capacity and a significant increase in mortality in patients with advanced heart 
failure. J Am Coll Cardiol, 39(11), 1780-6. 
Ix, J. H., Shlipak, M. G., Liu, H. H., Schiller, N. B. & Whooley, M. A. (2003). Association 
between renal insufficiency and inducible ischemia in patients with coronary artery 
disease: the heart and soul study. J Am Soc Nephrol, 14(12), 3233-8. 
Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010). Combination of loop diuretics with 
thiazide-type diuretics in heart failure. J Am Coll Cardiol, 56(19), 1527-34. 
Khan, W., Deepak, S. M., Coppinger, T., Waywell, C., Borg, A., Harper, L., Williams, S. G., & 
Brooks, N. H. (2006). Beta blocker treatment is associated with improvement in 
renal function and anaemia in patients with heart failure. Heart, 92(12), 1856-7. 
Keith, D. S., Nichols, G. A., Gullion, C. M., Brown, J. B. & Smith, D. H. (2004). Longitudinal 
follow-up and outcomes among a population with chronic kidney disease in a large 
managed care organization. Arch Int Med, 164(6), 659-63 
Kim, W.Y., Huh, J. W., Lim, C. M., Koh, Y. & Hong, S.B. (2011). Analysis of progression in 
risk, injury, failure, loss, and end-stage renal disease classification on outcome in 
patients with severe sepsis and septic shock. J Crit Care, 
doi:10.1016/j.physletb.2003.10.071 
Kittleson, M., Hurwitz, S., Shah, M. R., Nohria, A., Lewis, E., Givertz, M., Fang, J., Jarcho, J., 
Mudge, G., & Stevenson, L. W. (2003). Development of circulatory-renal limitations 
to angiotensin-converting enzyme inhibitors identifies patients with severe heart 
failure and early mortality. J Am Coll Cardiol, 41(11), 2029-35. 
Koniari, K., Nikolaou, M., Paraskevaidis, I., & Parissis, J. (2010). Therapeutic options for the 
management of the cardiorenal syndrome. Int J Nephrol, 2011, 194910. 
Konstam, M. A., Gheorghiade, M., Burnett, J. C., Jr., Grinfeld, L., Maggioni, A. P., Swedberg, 
K., Udelson, J. E., Zannad, F., Cook, T., Ouyang, J., Zimmer, C., & Orlandi, C. 
(2007). Effects of oral tolvaptan in patients hospitalized for worsening heart failure: 
the EVEREST Outcome Trial. JAMA, 297(12), 1319-31. 
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, 
R. D., Lau, J., Eknoyan, G.; National Kidney Foundation. (2003). National Kidney 
Foundation practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. Ann Intern Med, 139(2), 137-47. 
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The effect of angiotensin-
converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study 
Group. N Engl J Med, 329(20), 1456-62. 
Licata, G., Di Pasquale, P., Parrinello, G., Cardinale, A., Scandurra, A., Follone, G., Argano, 
C., Tuttolomondo, A., & Paterna, S. (2003). Effects of high-dose furosemide and 
www.intechopen.com
 Sub-Types and Therapeutic Management of the Cardiorenal Syndrome 
 
145 
small-volume hypertonic saline solution infusion in comparison with a high dose 
of furosemide as bolus in refractory congestive heart failure: long-term effects. Am 
Heart J, 145(3), 459-66. 
Linde, T., Wikstrom, B., Andersson, L. G., & Danielson, B. G. (1996). Renal anaemia 
treatment with recombinant human erythropoietin increases cardiac output in 
patients with ischaemic heart disease. Scand J Urol Nephrol, 30(2), 115-20. 
Low, I., Grutzmacher, P., Bergmann, M., & Schoeppe, W. (1989). Echocardiographic findings 
in patients on maintenance hemodialysis substituted with recombinant human 
erythropoietin. Clin Nephrol, 31(1), 26-30. 
Low-Friedrich, I., Grutzmacher, P., Marz, W., Bergmann, M., & Schoeppe, W. (1991). 
Therapy with recombinant human erythropoietin reduces cardiac size and 
improves heart function in chronic hemodialysis patients. Am J Nephrol, 11(1), 54-
60. 
Marenzi, G., Grazi, S., Giraldi, F., Lauri, G., Perego, G., Guazzi, M., Salvioni, A., & Guazzi, 
M. D. (1993). Interrelation of humoral factors, hemodynamics, and fluid and salt 
metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J 
Med, 94(1), 49-56. 
Massie, B. M., O'Connor, C. M., Metra, M., Ponikowski, P., Teerlink, J. R., Cotter, G., 
Weatherley, B. D., Cleland, J. G., Givertz, M. M., Voors, A., DeLucca, P., Mansoor, 
G. A., Salerno, C. M., Bloomfield, D. M., & Dittrich, H. C. (2010). Rolofylline, an 
adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med, 363(15), 
1419-28. 
McCullough, P. A. & Lepor, N. E. (2005). Piecing together the evidence on anemia: the link 
between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med, 
6(Suppl 3), S4-12. 
Mullens, W., Abrahams, Z., Francis, G. S., Sokos, G., Taylor, D. O., Starling, R. C., Young, J. 
B. & Tang, W. H. (2009). Importance of venous congestion for worsening of renal 
function in advanced decompensated heart failure. J Am Coll Cardiol 53(7), 589-96. 
Muntner, P., He, J., Astor, B. C., Folsom, A.R. & Coresh, J. (2005). Traditional and 
nontraditional risk factors predict coronary heart disease in chronic kidney disease: 
results from the atherosclerosis risk in communities study. J Am Soc Nephrol, 16(2), 
529-38. 
Nagashima, K., & Karasawa, A. (1996). Effects of KW-3902 (8-(noradamantan-3-yl)-1,3-
dipropylxanthine), an adenosine A1-receptor antagonist, on urinary excretions of 
various electrolytes in rats. Biol Pharm Bull, 19(7), 940-3. 
Nohria, A., Hasselblad, V., Stebbins, A., Pauly, D. F., Fonarow, G. C., Shah, M., Yancy, C. 
W., Califf, R. M. , Stevenson, L. W. & Hill, J. A. (2008). Cardiorenal interactions: 
Insights from the ESCAPE trial. J Am Coll Cardiol, 51(13), 1268-74. 
Palazzuoli, A., Silverberg, D., Iovine, F., Capobianco, S., Giannotti, G., Calabro, A., 
Campagna, S. M., & Nuti, R. (2006). Erythropoietin improves anemia exercise 
tolerance and renal function and reduces B-type natriuretic peptide and 
hospitalization in patients with heart failure and anemia. Am Heart J, 152(6), 1096 
e1099-1115. 
www.intechopen.com
 Chronic Kidney Disease 
 
146 
Parikh, N. I., Hwang, S. J., Larson, M. G., Meigs, J. B., Levy, D. & Fox, C. S. (2006). 
Cardiovascular disease risk factors in chronic kidney disease: overall burden and 
rates of treatment and control. Arch Intern Med, 166(17), 1884-91. 
Paterna, S., Di Pasquale, P., Parrinello, G., Amato, P., Cardinale, A., Follone, G., Giubilato, 
A., & Licata, G. (2000). Effects of high-dose furosemide and small-volume 
hypertonic saline solution infusion in comparison with a high dose of furosemide 
as a bolus, in refractory congestive heart failure. Eur J Heart Fail, 2(3), 305-13. 
Publication Committeee for the VMAC Investigators (2002). Intravenous nesiritide vs 
nitroglycerin for treatment of decompensated congestive heart failure: a 
randomized controlled trial. JAMA, 287(12), 1531-40. 
Ricci, Z., Cruz, D. & Ronco C. (2008). The RIFLE criteria and mortality in acute kidney 
injury: A systematic review. Kidney Int, 73(5), 538-46. 
Rimondini, A., Cipolla, C. M., Della Bella, P., Grazi, S., Sisillo, E., Susini, G., & Guazzi, M. D. 
(1987). Hemofiltration as short-term treatment for refractory congestive heart 
failure. Am J Med, 83(1), 43-8. 
Ronco, C., Haapio M., House, A. A., Anavekar N. & Bellomo, R. (2008). Cardiorenal 
Syndrome. J Am Coll Cardiol, 52(19), 1527-39. 
Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K. (2005). Short-term risk of 
death after treatment with nesiritide for decompensated heart failure: a pooled 
analysis of randomized controlled trials. JAMA, 293(15), 1900-5. 
Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005). Risk of worsening renal 
function with nesiritide in patients with acutely decompensated heart failure. 
Circulation, 111(12), 1487-91. 
Sands, J. M. (2003). Mammalian urea transporters. Annu Rev Physiol, 65, 543-66. 
Schrier, R. W., Gross, P., Gheorghiade, M., Berl, T., Verbalis, J. G., Czerwiec, F. S., & Orlandi, 
C. (2006). Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for 
hyponatremia. N Engl J Med, 355(20), 2099-112. 
Schrier, R. W., Masoumi, A., & Elhassan, E. (2009). Role of vasopressin and vasopressin 
receptor antagonists in type I cardiorenal syndrome. Blood Purif, 27(1), 28-32. 
Sharma, R., Francis, D. P., Pitt, B., Poole-Wilson, P. A., Coats, A. J. & Anker, S. D. (2004). 
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of 
the ELITE II trial. Eur Heart J, 25(12), 1021-8. 
Shlipak, M. G., Heidenreich, P. A., Noguchi, H., Chertow, G. M., Browner, W. S. & 
McClellan, M. B. (2002). Association of renal insufficiency with treatment and 
outcomes after myocardial infarction in elderly patients. Ann Intern Med, 137(7), 
555-62. 
Siew, E. D., Ware, L. B. & Ikizler, T. A. (2011). Biological markers of acute kidney injury. J 
Am Soc Nephrol, 22(5), 810-20. 
Silverberg, D. S., Wexler, D., Blum, M., Keren, G., Sheps, D., Leibovitch, E., Brosh, D., 
Laniado, S., Schwartz, D., Yachnin, T., Shapira, I., Gavish, D., Baruch, R., Koifman, 
B., Kaplan, C., Steinbruch, S., & Iaina, A. (2000). The use of subcutaneous 
erythropoietin and intravenous iron for the treatment of the anemia of severe, 
resistant congestive heart failure improves cardiac and renal function and 
www.intechopen.com
 Sub-Types and Therapeutic Management of the Cardiorenal Syndrome 
 
147 
functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol, 
35(7), 1737-44. 
Smith, G. L., Lichtman, J. H., Bracken, M. B., Shlipak, M. G., Phillips, C. O., DiCapua, P. & 
Krumholz, H. M. (2006). Renal impairment and outcomes in heart failure: 
systematic review and meta-analysis. J Am Coll Cardiol, 47(10), 1987-96. 
Smith, G. L., Masoudi, F. A., Shlipak, M. G., Krumholz, H. M. & Parikh, C. R. (2008). Renal 
impairment predicts long-term mortality risk after acute myocardial infarction. J 
Am Soc Nephrol, 19(1), 141-50. 
Swedberg, K., Eneroth, P., Kjekshus, J., & Snapinn, S. (1990). Effects of enalapril and 
neuroendocrine activation on prognosis in severe congestive heart failure (follow-
up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol, 66(11), 
40D-44D; discussion 44D-45D. 
Tanaka, K., Ito, M., Kodama, M., Maruyama, H., Hoyano, M., Mitsuma, W., Iino, N., Hirono, 
S., Okura, Y., Gejyo, F., Tanabe, N., & Aizawa, Y. (2007). Longitudinal change in 
renal function in patients with idiopathic dilated cardiomyopathy without renal 
insufficiency at initial diagnosis. Circ J, 71(12), 1927-31. 
The National Heart, Lung and Blood Institute Working Group. (2004) Executive Summary, 
In: Cardio-Renal Connections in Heart Failure and Cardiovascular Disease, 06.23.2011, 
Available from: www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm 
The SOLVD Investigators (1991). Effect of enalapril on survival in patients with reduced left 
ventricular ejection fractions and congestive heart failure. New England Journal of 
Medicine, 325(5), 293-302. 
The SOLVD Investigators (1992). Effect of enalapril on mortality and the development of 
heart failure in asymptomatic patients with reduced left ventricular ejection 
fractions. New England Journal of Medicine, 327(10), 685-91. 
Toblli, J. E., Lombrana, A., Duarte, P., & Di Gennaro, F. (2007). Intravenous iron reduces NT-
pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal 
insufficiency. J Am Coll Cardiol, 50(17), 1657-65. 
Uchino, S., Bellomo, R., Goldsmith, D., Bates, S. & Ronco, C. (2006). An Assessment of the 
RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med, 34(7), 
1913-17. 
Uthoff, H., Breidthardt, T., Klima, T., Aschwanden, M., Arenja, N., Socrates, T., Heinisch, C., 
Noveanu, M., Frischknecht, B., Baumann, U., Jaeger, K. A. & Mueller, C. (2011) 
Central venous pressure and impaired renal function in patients with acute heart 
failure. Eur J Heart Fail 13(4), 432-9. 
Virani, S. A., Khosla A. & Levin A. (2008). Chronic kidney disease, heart failure and anemia. 
Can J Cardiol, 24(Suppl B), 22B-24B. 
Wali, R. K. & Henrich, W. L. (2005). Chronic kidney disease: a risk factor for cardiovascular 
disease. Cardiol Clin, 23(3), 343-62. 
Wali, R. K., Iyengar, M., Beck, G. J., Chartyan, D. M., Chonchol, M., Lukas, M. A., Cooper, 
C., Himmelfarb, J., Weir, M. R., Berl, T., Henrich, W. L., & Cheung, A. K. (2011). 
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney 
disease: a meta-analysis of randomized trials. Circ Heart Fail, 4(1), 18-26. 
www.intechopen.com
 Chronic Kidney Disease 
 
148 
Wattanakit, K., Coresh, J., Muntner, P., Marsh, J. & Folsom, A. R. (2006). Cardiovascular risk 
among adults with chronic kidney disease, with or without prior myocardial 
infarction. J Am Coll Cardiol, 48(6), 1183-9. 
Yao, K., Kusaka, H., Sato, K., & Karasawa, A. (1994). Protective effects of KW-3902, a novel 
adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure 
in rats. Jpn J Pharmacol, 65(2), 167-70. 
www.intechopen.com
Chronic Kidney Disease
Edited by Prof. Monika Göőz
ISBN 978-953-51-0171-0
Hard cover, 444 pages
Publisher InTech
Published online 16, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Chronic kidney disease is an increasing health and economical problem in our world. Obesity and diabetes
mellitus, the two most common cause of CKD, are becoming epidemic in our societies. Education on healthy
lifestyle and diet is becoming more and more important for reducing the number of type 2 diabetics and
patients with hypertension. Education of our patients is also crucial for successful maintenance therapy. There
are, however, certain other factors leading to CKD, for instance the genetic predisposition in the case of
polycystic kidney disease or type 1 diabetes, where education alone is not enough.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Margot Davis and Sean A. Virani (2012). Sub-Types and Therapeutic Management of the Cardiorenal
Syndrome, Chronic Kidney Disease, Prof. Monika Göőz (Ed.), ISBN: 978-953-51-0171-0, InTech, Available
from: http://www.intechopen.com/books/chronic-kidney-disease/sub-types-and-therapeutic-management-of-
the-cardiorenal-syndrome
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
